CANbridge Pharmaceuticals to Terminate Agreements to Downsize Operations in U.S.A

MT Newswires Live

Oct 25, 2024

CANbridge Pharmaceuticals (HKG:1228) served a notice of termination of its exclusive UMass license agreement with the University of Massachusetts.

The company is also actively negotiating the terms to cancel its lease of the group's office and laboratory space in Boston under its downsizing plan, a Friday Hong Kong bourse filing said.

Under the UMass license agreement, the company obtained global rights to develop, manufacture, and commercialize a certain spinal muscular atrophy-treating gene therapy in Jan. 2023. The termination will take effect within 60 days from the notice date.

The biopharmaceutical company's shares closed nearly 4% lower on Friday.

Price (HKD): $0.24, Change: $-0.0090, Percent Change: -3.60%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2478988910"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2478988910\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2478988910?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-25 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478988910","market":"nz","top_or_hot":-1,"title":"CANbridge Pharmaceuticals to Terminate Agreements to Downsize Operations in U.S.A","media":"MT Newswires Live","content":"<html><body><p> CANbridge Pharmaceuticals (HKG:1228) served a notice of termination of its exclusive UMass license agreement with the University of Massachusetts.</p><p>The company is also actively negotiating the terms to cancel its lease of the group's office and laboratory space in Boston under its downsizing plan, a Friday Hong Kong bourse filing said.</p><p>Under the UMass license agreement, the company obtained global rights to develop, manufacture, and commercialize a certain spinal muscular atrophy-treating gene therapy in Jan. 2023. The termination will take effect within 60 days from the notice date.</p><p>The biopharmaceutical company's shares closed nearly 4% lower on Friday.</p><p>Price (HKD): $0.24, Change: $-0.0090, Percent Change: -3.60%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANbridge Pharmaceuticals to Terminate Agreements to Downsize Operations in U.S.A</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANbridge Pharmaceuticals to Terminate Agreements to Downsize Operations in U.S.A\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-25 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CANbridge Pharmaceuticals (HKG:1228) served a notice of termination of its exclusive UMass license agreement with the University of Massachusetts.</p><p>The company is also actively negotiating the terms to cancel its lease of the group's office and laboratory space in Boston under its downsizing plan, a Friday Hong Kong bourse filing said.</p><p>Under the UMass license agreement, the company obtained global rights to develop, manufacture, and commercialize a certain spinal muscular atrophy-treating gene therapy in Jan. 2023. The termination will take effect within 60 days from the notice date.</p><p>The biopharmaceutical company's shares closed nearly 4% lower on Friday.</p><p>Price (HKD): $0.24, Change: $-0.0090, Percent Change: -3.60%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2478988910","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478988910","pubTimestamp":1729854451,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CANbridge Pharmaceuticals  served a notice of termination of its exclusive UMass license agreement with the University of Massachusetts.The company is also actively negotiating the terms to cancel its lease of the group's office and laboratory space in Boston under its downsizing plan, a Friday Hong Kong bourse filing said.Under the UMass license agreement, the company obtained global rights to develop, manufacture, and commercialize a certain spinal muscular atrophy-treating gene therapy in Jan. 2023. The termination will take effect within 60 days from the notice date.The biopharmaceutical company's shares closed nearly 4% lower on Friday.Price : $0.24, Change: $-0.0090, Percent Change: -3.60%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4023":"应用软件","01228":"北海康成-B","BK1161":"生物科技","BK4588":"碎股","HKD":"尚乘数科","BK4526":"热门中概股","BK4585":"ETF&股票定投概念"},"translate_title":"CANbridge Pharmaceuticals将终止缩减美国业务的协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01228":0.9,"HKD":1},"content_text":"CANbridge Pharmaceuticals (HKG:1228) served a notice of termination of its exclusive UMass license agreement with the University of Massachusetts.The company is also actively negotiating the terms to cancel its lease of the group's office and laboratory space in Boston under its downsizing plan, a Friday Hong Kong bourse filing said.Under the UMass license agreement, the company obtained global rights to develop, manufacture, and commercialize a certain spinal muscular atrophy-treating gene therapy in Jan. 2023. The termination will take effect within 60 days from the notice date.The biopharmaceutical company's shares closed nearly 4% lower on Friday.Price (HKD): $0.24, Change: $-0.0090, Percent Change: -3.60%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}